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ABSTRACT
A simple, rapid and stability-indicating reverse-phase liquid chromatographic (RP-LC) method was developed for the separation
of pindolol (PDL) and its related substances in the presence of its degradation products generated from forced decomposition studies.
The chromatographic separation was achieved on a C18 Inertsil ODS-3V column (250 mm × 4.6 mm i.d.), using a mobile phase of
20 mM sodium dihydrogen orthophosphate-acetonitrile containing orthophosphoric acid to maintain pH at 4.0. Gradient elution was
used at a flow rate of 1.0 mL/min. The UV detector was operated at 205 nm and the column temperature was maintained at ambient.
Separation of PDL enantiomers was achieved on normal phase liquid chromatography (NP-LC) using a chiral pack AD-H (250 mm
× 4.6 mm i.d.) column, with mobile phase consisting of n-hexane : ethanol : diethylamine (860 : 140 mL : 0.05%, v/v). A flow rate of
0.9 mL/min and detection wavelength of 215 nm were used. The method was validated for specificity, linearity and range, precision,
accuracy, solution stability, robustness, limit of detection (LOD) and limit of quantification (LOQ). Selectivity of the RP-LC method
was validated by subjecting the stock solution of PDL to acidic, basic, photolysis oxidative and thermal degradation. The calibration curve was found to be linear in the concentration range of 0.01 - 100 µg/mL (r2 = 0.9998) and 0.001 - 50 µg/mL (r2 = 0.9982) of
PDL for the RP-LC and NP-LC method, respectively. The peaks of degradation products did not interfere with that of pure PDL. The
utility of the developed method was examined for chemical and chiral purity by analyzing the tablets containing PDL and also by
determining the related substances of PDL. The results of analysis were supported by statistical parameters.
Key words: pindolol, related substance, chiral separation, validation, forced degradation

INTRODUCTION
Pindolol (PDL) (Figure 1A), a synthetic beta-adrenergic receptor blocking agent(1) with intrinsic sympathomimetic activity, is 1-(indol-4-yloxy)-3-(isopropylamino)-2propanol. It is an effective agent for treating hypertension
in pregnancy, a disease that complicates up to 5% of all
pregnancies(2-5). PDL is a non-selective beta-adrenergic
antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (ISA) in therapeutic dosage ranges
but does not possess quinidine-like membrane-stabilizing
activity. PDL causes no changes in utero or in umbilicoplacental vascular impedance or blood flow, has no effect
on fetal haemodynamics and does not affect fetal cardiac
function(3). PDL non-selectively blocks beta-1 adrenergic
receptors mainly in the heart, inhibiting the effects of
epinephrine and norepinephrine, resulting in a decrease
* Author for correspondence. Email: jseetharam@yahoo.com

in heart rate and blood pressure. PDL inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production and therefore inhibits vasoconstriction
and water retention due to angiotensin II and aldosterone,
respectively. It is marketed as a racemic mixture of the
(−)-S and (+)-R enantiomers, because PDL is eliminated
stereoselectively by the kidney(6). It is moderately lipidsoluble(7) and about 40 - 60% is reported to be bound to
plasma proteins(8).
A few LC methods for quantification of PDL in biosamples have been reported using chiral columns and
derivative method for separation(10,11). Determination
of PDL in human serum or urine has also been achieved
by LC/MS/MS(12,13). The United States Pharmacopeia
(USP) describes the HPLC method with the mobile phase
consisting of 0.05 M sodium acetate (pH 5.0) buffer and
acetonitrile (65 : 35, v/v) on a 150 × 4.6 mm column using
UV detection at 219 nm for the assay of PDL. In this
method, the low concentration of acetonitrile resulted
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in less resolution between PDL and impurities, while
increased acetonitrile concentration also resulted poor
resolution between PDL and impurities with longer retention times. Further, the USP method described a TLC
method for the determination of impurities and for the
assay of formulations containing PDL. This method limits
the detection of any individual impurity to a maximum of
0.5%. The British Pharmacopoeia (BP) describes a TLC
method to report any impurity that exists greater than
0.3%. The present study reports for the first time the development and validation of RP-LC method for the assay of
PDL and its related substances (Figure 1B) in shorter run
time and at higher detection levels. No method has been
reported so far for the analysis of PDL and its related
substances. Further, the drug substance was subjected to
stress degradation conditions viz., acidic, basic, oxidation,
photolysis and thermal degradation in liquid and solid
states to evaluate the PDL purity. The proposed method
is observed to be specific as it can be used to determine
the presence of its degradation products. In addition, the
separation of enantiomers was effectively achieved. This
observation was not described in the official methods.

(A)

MATERIALS AND METHODS
I. Chemicals and Reagents
The pure compound of PDL was obtained from
Novartis Pharmaceuticals, India. HPLC-grade acetonitrile and n-hexane were purchased from Spectrochem Pvt.
Ltd., India. Sodium dihydrogen orthophosphate, orthophosphoric acid, hydrochloric acid, sodium hydroxide,
diethylamine and hydrogen peroxide were obtained from
Merck (Darmstadt, Germany). HPLC-grade ethanol was
obtained from Hayman, England. HPLC-grade water was
obtained from a Milli-Q water purification system (Millipore, MA, USA) and used throughout the study.
II. Instrumentation
For PDL and its related substances, a Waters 2695
separation module system consisting of an online
degasser, quaternary pump, auto-sampler equipped with
cooling system, thermostat column compartment and 2996
module photo-diode array (PDA) detector was used. An
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Inertsil C18 column (250 mm × 4.6 mm i.d., particle size
of 5 µm, G L Science, Japan) was used in the study. The
data were processed on the Empower software version
2.0. Mobile phase and sample/standard preparations were
degassed using a sonicator (S. V. Scientific, India).
For separation of (R)- and (S)- enantiomers of PDL,
a Waters 2695 separation module system consisting of a
quaternary pump, auto-sampler equipped with cooling
system, thermostat column compartment and 2487
module dual wavelength detector was used. A chiral
pack AD-H column (250 mm × 4.6 mm i.d., particle size
of 5 µm, Daicel, Japan) was used in the study.
III. Chromatographic Conditions
The mobile phase consisting of (A) 20 mM sodium
dihydrogen orthophosphate and orthophosphoric acid
in water of pH 4.0 and (B) acetonitrile was used, with a
gradient programmed pump to deliver the buffer and
solvent to the column at a flow rate of 1.0 mL/min. The
solvent and buffer delivery pump was programmed to
gradient system and it started with initially 30% of acetonitrile and 70% of phosphate buffer and maintained up to
4 min, then the acetonitrile and buffer ratio was increased
to 70% and 30% respectively in 10 min and maintained
at the same ratio for 5 min. The column was re-equilibrated for 5 min. The mobile phase was filtered through
a 0.45-µm filter (Millipore, Bedford, USA). Water and
acetonitrile in the ratio of 70 : 30 v/v was used as diluent
for sample and standard preparations and the same was
injected as blank. The UV detector was operated at 205
nm and peak purity was determined over 200 - 400 nm
using a custom-made PDL spectrum match library. The
column temperature was maintained at ambient.
The separation of enantiomers was achieved on a
chiral pack AD-H (250 mm × 4.6 mm i.d.) column, using
a mobile phase consisting of n-hexane-ethanol-diethylamine (860 mL : 140 mL : 0.05%, v/v) with an isocratic
pump to deliver the solvent to the column at a flow rate
of 0.9 mL/min. An n-hexane and ethanol mixture in the
ratio 50 : 50 v/v was used as diluent for sample and standard preparation and the same was injected as blank.
The UV detector was operated at 215 nm and the column
temperature was maintained at ambient.
IV. Procedures
(I) Preparation of Stock and Standard Solutions of PDL and
Related Substances
A stock solution of PDL (0.2 mg/mL) and impurity solution (0.1 mg/mL) was prepared by dissolving
an appropriate amount of substance in diluent (water :
acetonitrile ; 700 mL : 300 mL, v/v). For NP-LC analysis,
(R)-enantiomer, (S)-enantiomer and racemate stock solutions (0.1 mg/mL) were prepared in diluent (n-hexane :
ethanol; 450 mL : 550 mL, v/v).

I. Analysis of Tablets
Twenty tablets of PDL were finely powdered. An
amount equivalent to 20 mg of the drug was weighed
accurately and transferred into a 100-mL beaker. Using
a mechanical stirrer, the powder was completely disintegrated in mobile phase. The solution was filtered and the
filtrate was made up to 100 mL with the mobile phase. It
was further diluted, as required for analysis.
II. Linearity and Range
The test solutions were prepared from the stock
solution of PDL so as to contain the drug in the range of
0.01 - 100 µg/mL. The solutions were injected in triplicate
into the HPLC column, using a constant injection volume
of 10 µL and the chromatograms were recorded. The
peak area versus concentration data was treated by leastsquares linear regression analysis. Chromatograms were
recorded using the above test solutions for three consecutive days in the same concentration range. The % Relative
Standard Deviation (RSD) values were calculated.
III. Precision
Intra-day precision and inter-day precision were
evaluated by analyzing six replicates of three different
concentrations (20, 60, 80 µg/mL) on the same day and
on different days, respectively. The respective % Relative
Standard Deviation (RSD) values were calculated.
IV. Accuracy
The accuracy of the assay method was evaluated
in triplicate at three concentration levels (20, 60 and
80 µg/mL). It was also evaluated by fortifying a mixture
of formulation sample with three known concentrations of
the drug. The recovery of the added drug was determined.
V. Specificity and Selectivity
Specificity of the method was established through
study of resolution factors of the drug peak from the
nearest resolving peak and also among all the other
peaks (14). The presence/absence of peaks due to excipients, impurities and degraded products was examined to
study the interference from these substances in the assay
of the drug(15).
VI. LOD and LOQ
Determination of the signal-to-noise ratio was
performed by comparing measured signals from samples
with known low concentrations of analyte with those of
blank samples and by establishing the minimum concentration at which the analyte can be reliably detected and
quantified.
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The values of LOD and LOQ were determined at a
signal to noise ratio of 3 : 1 and 10 : 1, respectively by
injecting a series of test solutions of known concentrations within linearity range (15). Precision study was also
carried out at the LOQ level by injecting six preparations.
VII. Robustness
To determine the robustness of the developed method,
experimental conditions were deliberately altered to check
the reproducibility and quantitative recovery of the drug.
This was carried out by maintaining the flow rate of the
mobile phase in the range of 0.8 - 1.2 mL/min, column
temperature in the range of 22 - 30°C and the strength of
the phosphate buffer was changed from 20 mM to 10 mM
and the resolution of PDL and related substances was evaluated. Chromatograms were recorded and compared with
those obtained under optimum chromatographic conditions.
In case of chiral separations n-hexane, ethanol and diethylamine compositions were varied from 830 mL to 890 mL
v/v, 170 mL to 110 mL v/v and 0.03% to 0.07%, respectively.
VIII. Solution Stability and Mobile Phase Stability
The solution stability of PDL in the assay method
was carried out by leaving both the test solutions of the
sample and reference standard in tightly capped ambercolored volumetric flasks separately, at room temperature, up to the study period of 72 h. The chromatograms
of these solutions were recorded separately at an interval
of 1 h up to 72 h and the peak responses were compared.
The mobile phase stability was carried out by
assaying the freshly prepared bulk drug and formulation
sample solutions against freshly prepared reference/standard solution at an interval of 8 h. The same mobile phase
was used throughout the experiment. % Relative Standard Deviation (RSD) values were calculated for mobile
phase and solution stability experiments. In the case of
chiral separations, solution stability and mobile phase
stability were studied for 24 h.
IX. Oxidation of PDL
For oxidation study, 5.0 mL of stock solution of
PDL (50 µg/mL) was transferred to a 25-mL ambercolored volumetric flask and made up to volume with 3%
hydrogen peroxide. The flask was placed at 80°C for 8 h,
cooled to room temperature and the volume was readjusted with 3% hydrogen peroxide. Then the solution was
filtered through a 0.45-µm syringe filter and 10 µL solution was injected into the liquid chromatographic system
to detect peaks of degradation due to oxidation.
X. Thermal Degradation of PDL
This was carried out by transferring 5.0 mL of PDL
(50 µg/mL) into a 25-mL volumetric flask and diluted to

the mark with the mobile phase. The flask was closed and
placed at 80°C for 8 h, cooled to room temperature and
the volume of solution was readjusted with the diluent.
The chromatogram was recorded.
XI. Degradation of PDL by an Acid
For this study, 5.0 mL of PDL (50 µg/mL) was transferred into a 25-mL volumetric flask and the volume was
made up to the mark with 1 M hydrochloric acid. The
flask was placed at 80°C for 8 h, cooled to room temperature and the volume of solution was readjusted to 20 mL
with 1 M hydrochloric acid. The solution was adjusted to
neutral pH using 1 M sodium hydroxide to avoid column
damage at too acidic a condition, as it would lead to peak
splitting or to unsymmetrical peak shape. The neutral
solution was injected into the liquid chromatograph and
the chromatogram was recorded.
XII. Degradation of PDL by an Alkali
This was conducted by transferring 5.0 mL of PDL
(50 µg/mL) into a 25.0-mL volumetric flask and diluted
to the mark with 1 M sodium hydroxide. The flask was
kept at 80°C for 8 h, cooled to room temperature and
the volume was readjusted to 20 mL with 1 M sodium
hydroxide. The solution was neutralized with 0.1 M hydrochloric acid solution and the chromatogram was recorded.
XIII. Photodegradation of PDL
For photodegradation studies, 5.0 mL of PDL
(50 µg/mL) was transferred into a 25.0-mL volumetric
flask and diluted to the mark with diluent. The flask was
exposed to UV light for 8 h continuously. The experiment was also repeated with solid drug sample (10 µg/mL
in diluent). Both solutions were separately injected into
the liquid chromatograph and the chromatograms were
recorded.

RESULTS AND DISCUSSION
I. Method Development and Optimization for PDL and its
Related Substances
Identification and control of impurities for drug
substances is a critical task in pharmaceutical process
development for quality and safety. The most commonly
used analytical technique for impurity analysis in drug
substances and a drug product is undoubtedly a chromatographic method, namely high performance liquid chromatography (HPLC). Impurity profiling is typically performed
by HPLC and impurities are further tested for identification
and confirmation by other techniques. Upon identification
of the impurity, the impurity formation was monitored and
controlled throughout the synthesis. It is demonstrated that
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identification and monitoring of the unknown or known
impurities enabled chemists to pinpoint the chemical step
of impurity generation, aiding the effort to reduce or even
eliminate the impurity in the drug substances.
PDL is a weak base with pKa of 9.7. The selection of
buffer assumes importance. Ammonium acetate buffer was
found to be unsuitable due to poor resolution and the UV
cut off at 215 nm. Gradient program was employed using
phosphate buffer and acetonitrile with an initial ratio of
60 : 40. Due to less interaction of the compound with the
stationary phase, PDL and impurities were eluted very
early and the peaks were unsymmetrical in nature. Moreover, the peaks of degradants were not separated from that
of the pure drug. Well-resolved and symmetric peaks were
obtained with the mobile phase consisting of sodium dihydrogen orthophosphate buffer of pH 4.0 ± 0.1 and acetonitrile. In order to optimize the chromatographic conditions,
the effect of composition of mobile phase, flow rate and the
detection wavelength were investigated. Ideal chromatographic conditions were observed with the mobile phase

consisting of 20 mM sodium dihydrogen orthophosphateacetonitrile containing ortho-phosphoric acid adjusted to
pH 4.0. The gradient program started initially with 30%
of acetonitrile and 70% of phosphate buffer and maintained up to 4 min, and then the ratio of acetonitrile and
buffer was changed to 70 : 30 in 10 min and maintained at
the same ratio for 5 min. The column was re-equilibrated
for 5 min with a flow rate of 1.0 mL/min and a wavelength
of 205 nm was used throughout the run time. Typical
chromatograms of PDL and related substances overlaid
with blank are shown in Figure 2. The selection of wavelength to monitor the quality evaluation of drug substance
and related impurities was done by overlaying the individual UV spectra of PDL and its impurities-I, II, III and
IV (Figure 3). The wavelength of 205 nm was selected due
to maximum absorbance for all the related impurities and
drug substance. From the purity plot of PDL, lower purity
angle value of PDL compared to that of the purity threshold
(Table 1 and Figure 4) revealed that the PDL was free from
interference from its impurities and its degradants. This

Table 1. System suitability parameters
Name

Retention time (min)

Purity angle

Purity threshold

USP tailing

Resolution

USP plate count

PDL

3.383

0.557

0.567

1.201

Not applicable

5159

Impurity-I

5.287

0.537

0.574

1.180

8.160

7556

Impurity-II

8.267

0.497

0.500

1.089

10.572

11093

Impurity-II

9.261

0.523

0.592

0.958

3.639

27996

Impurity-IV

10.089

0.622

0.630

1.211

3.287

22483

0.040
0.035

0.010

Impurity-IV- 10.126

0.015

Impurity-III- 9.273

Impurity-I- - 5.293

0.020

Impurity-II- 8.274

0.025

Pindolol - 3.431

Absorbance units

0.030

0.005
0.000

1.00

2.00 3.00

4.00

5.00

6.00

7.00

8.00

9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00

Time (min)

Figure 2. A typical chromatogram of PDL and its related substances overlaid with blank using an intial eluent of 70 : 30 (v/v, 20 mM sodium
dihydrogen orthophosphate of pH 4.0 – acetonitrile) ramped to 30 : 70 within 10 min (UV absorption at 205 nm).
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Figure 3. UV spectra of PDL and its related substances overlaid.
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Figure 4. Purity plot of PDL.

was also evident by comparing the 3D plot of the PDL standard with that of the degraded product. The representative
3D diagrams for pure PDL and its related substances are
shown in Figure 5.
II. Method Development and Optimization for (R) and (S)
Enantiomers of PDL
The method development strategies adopted using
chiral pack AD-H column involve different experiments based on the nature and structure of the compound.
The design of mobile phase consists of a combination
of alkane and polar alcohols based on normal or polar

interactive modes. Attempts to separate (R) and (S)
isomers of PDL using chiral columns in the reverse phase
were not successful. The use of normal phase chromatography employing various chiral columns (chiral cel-OJ,
chiral cel-OD) were also not successful. When using chromatographic conditions, such as flow rate of 0.9 mL/min
and mobile phase of n-hexane and 2-propanol (800 mL :
200 mL, v/v) mixture on a chiral pack OD-H column with
dimension 250 mm × 4.6 mm, 5 µm, it was observed that the
(R) and (S) isomers of PDL were eluted as broad peaks with
longer retention times. However, an improvement in peak
shapes was observed when a chiral pack AD-H column with
n-hexane and ethanol ratio (860 mL : 140 mL) mobile phase
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and the same flow rate were used. However, there were still
certain constraints like longer retention times and poor
separation between the enantiomers. Due to the presence of
amide functional group in PDL, 0.05% of diethylamine was
introduced to the above mobile phase, i.e. n-hexane : ethanol
(860 mL : 140 mL, v/v), which gave comparatively good

peak shapes as well as good resolution. In the present optimized method, the typical retention times of (S)-enantiomer
and (R) enantiomer of PDL were noticed to be 10.1 min and
13.1 min, respectively. Typical chromatograms of the PDL
racemate are shown in Figure 6. The resolution between the
two enatiomers was about 5.923. Diluent, n-hexane : ethanol
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0.08
0.06

Absorbance units

0.12

0.04
0.02
0.00
200.00
300.00
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(nm)

1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00

Time (min)

Figure 5. 3D plot of PDL standard and its related substances.
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Figure 6. Typical chromatogram of PDL enantiomers (racemate) at a concentration of 8 µg/mL using an isocratic eluent of n-hexane : ethanol
in 86 : 14 v/v ratio for 20 min (UV absorption at 215 nm).
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(1 : 1) was used as blank and there was no interference of
the blank and of excipients with (S) and (R) enantiomers of
PDL. The elution was monitored at 215 nm.
III. Precision
The % RSD values for intra-day and inter-day
precision study were found to be less than 0.5% and
0.8%, respectively, indicating that the method was sufficiently precise.
IV. Accuracy
The % recovery values of PDL in pharmaceutical
formulation ranged from 99.8 to 100.1 (Table 2). High
percentage recovery values revealed that the proposed
method is accurate and could be adopted for routine
quality control analysis.
V. Limit of Detection (LOD) and Limit of Quantification
(LOQ)
ICH guidelines(15) were followed to calculate the
values of LOD and LOQ for PDL and they were observed
to be 0.0030 µg/mL and 0.01 µg/mL, respectively. The
% RSD value was noticed to be less than 1.2 for related
substances at the LOQ concentration level.
VI. Linearity
The calibration plot for the assay of PDL was linear
over the investigated range of 0.01 - 100 µg/mL with a
correlation coefficient value of 0.9998. In the case of racemate, (R) and (S) enantiomers of PDL, the calibration plot
was noticed to be linear in the range of 0.001 - 50 µg/mL (r2
= 0.9982) and 0.002 - 50 µg/mL (r2 = 0.9989) respectively.
For the related substances, the values are given in Table 3.
Table 2. Recovery results of PDL sample
Added (µg) (n = 3)

Recovered (µg)

% Recovery

% RSD

50.1

50.0

99.8

0.8

100.5

100.6

100.1

0.9

150.2

150.4

100.1

1.1

VII. Robustness
Under the deliberately varied chromatographic conditions (flow rate, column temperature and composition of
organic solvent or buffer), the reproducibility of results
was observed to be reasonably good. Hence, it can be
concluded that the proposed method has good robustness
for the analysis of PDL in bulk or tablets.
VIII. Solution Stability and Mobile Phase Stability
The % RSD of the assay of PDL during solution
stability and mobile phase stability experiments were
found to be less than 0.9%. This indicated that the sample
solutions and mobile phases used during quantification of
PDL and its related substances were stable for at least 72 h.
IX. Results of Forced Degradation Studies
Forced degradation is the process of subjecting the
drug compound to extreme chemical and environmental
conditions to determine product breakdown levels, assess
preliminary degradation kinetics and identify degradants.
The ICH guideline indicates that stress testing is designed
to help determine the intrinsic stability of the molecule by
establishing degradation pathways, in order to identify the
likely degradation products and to validate the stabilityindicating power of the analytical procedures used. The
hydrolytic degradation of a newly proposed drug in acidic
and alkaline conditions can be studied by keeping the solution of pure drug in HCl and NaOH medium respectively at
room temperature over 12 h. If degradation is not observed
for more than 5% even after increasing the strength of the
acid or alkali, then the same solution can be refluxed for 8
h. Further, to examine the degradation by oxidation, it is
suggested to use hydrogen peroxide in the concentration
range of 3 - 30%. If degradation is not observed for more
than 5%, the same solution may be refluxed for 8 h.
Degradation was not observed in thet PDL sample
when it was subjected to acid, alkali and oxidation at
room temperature with 1 M hydrochloric acid, 1 M
sodium hydroxide and 3% hydrogen peroxide, respectively. However, when the same solutions were kept
at 80°C, degradation was observed under all the three
conditions and chromatograms of these solutions were
recorded. Oxidative degradation of PDL pure sample

Table 3. Related substances linearity and LOQ data (n = 6)
R2

LOQ (µg/mL)

Accuracy @ 50%

Accuracy @ 100%

Accuracy @ 150%

Impurity-I

0.9991

0.0206

101.1

99.1

98.4

Impurity-II

0.9994

0.0516

101.5

100.2

101.5

Impurity-III

0.9983

0.0509

99.5

99.7

99.5

Impurity-IV

0.9989

0.0510

98.7

100.9

99.3

Name
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Figure 7. A typical chromatogram of PDL exposed to 3% hydrogen peroxide.

Peak 1 - 3.145
pindolol - 3.541

(A)
0.40
0.35

0.25

HCl

0.20
Peak 3 - 10.648

Absorbance units

0.30

0.15
0.10
0.05
0.00
2.00

4.00

6.00

8.00

10.00

16.00

18.00

Time (min)
2.00

(B)

1.80
1.60

1.20
1.00
0.80

Absorbance units

1.40

0.60
0.40
0.20
0.00
200.00
250.00 Wavelength
(nm)
300.00
350.00
1.00

2.00

3.00

4.00

5.00

6.00

7.00

8.00

9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00

Time (min)

Figure 8. (A) A typical chromatogram of PDL exposed to 1 M hydrochloric acid.(B) 3D plot of PDL in acidic condition.
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yielded six degradation products as shown in Figure 7.
In acid hydrolysis of pure drug, two major degradation
products were observed (Figure 8A). Moreover, the 3D
plot of acid hydrolysis of PDL (Figure 8B) confirmed
(A)

the two major degradation products. Two major degradation products were also noticed in alkali hydrolysis
of PDL (Figure 9A) and this was evident from the 3D
plot of alkali hydrolysis of PDL (Figure 9B). However,
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Figure 9. (A) A typical chromatogram of PDL exposed to 1 M sodium hydroxide. (B) 3D plot of PDL in alkaline condition.
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Figure 10. A typical chromatogram of PDL solution exposed to UV light (photolysis).

Table 4. Summary of forced degradation results
Stress condition

Time (h)

% Assay of active substance

% Mass balance (% assay + impurity)

Acid hydrolysis (1 N HCl) reflux at 80°C

8

81.2

18.8

Base hydrolysis (1 N NaOH) reflux at 80°C

8

49.3

50.7

Oxidation (3% H2O2) reflux at 80°C

8

90.1

9.9

Thermal (80°C)

12

99.4

0.6

Photolysis

24

92.5

7.6

in order to avoid column damage, peak splitting and
unsymmetrical peak shapes.

Table 5. Analysis of PDL in pharmaceutical formulations
Formulation

Labeled
(mg)

Found*
(mg)

% RSD

% Recovery*

Visken®

5

4.95

0.96

99.0

10

9.96

0.82

99.6

15

15.06

0.74

100.4

*Average of nine determinations.

19 degradation products were found in the photolysis of
pure PDL (Figure 10). Peak purity test results confirmed
that the PDL peak was homogenous and pure in all the
analyzed stress samples. The mass balance assay due
to forced degradation is tabulated in Table 4. The clear
solution of PDL changed to pale pink, yellow and light
yellow under acidic, oxidation and photolytic conditions, but remained unchanged in alkaline condition. As
the sample solutions obtained during stress studies were
either too acidic or too basic, the solutions were neutralized before running the chromatograms. This was done

X. Analysis of Pharmaceutical Preparations
The proposed method was successfully applied to
the analysis of PDL in tablets and the results are shown
in Table 5. The low values of % RSD indicated high precision of the method. High percentage recovery values indicated that the commonly employed excipients, colloidal
silicon dioxide, magnesium stearate, microcrystalline
cellulose and pregelatinized starch did not interfere with
the analysis of PDL in tablets.

CONCLUSIONS
The proposed RP-LC and NP-LC methods were
observed to be precise, specific, accurate and stability
indicating. PDL and its related substances and enantiomers can be determined in bulk powder and pharmaceutical formulation in the presence of its degradation
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products. As a better alternative to the official methods,
the currently described LC method separates PDL and
its related substances within a short time span of 20 min.
Moreover, the separation of enatiomers was achieved
effectively while USP makes no mention about this.
ICH guidelines were followed throughout the study for
method validation and stress testing. In view of this, the
proposed method could be adopted for quality control
and routine analysis.
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